Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Moderately to Severely Active Crohn's Disease (GALAXI)
NCT03466411Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 43
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Crohn's Disease Activity Index at 12 weeks, Clinical Response and Clinical Remission at 48 weeks and 3 more. Started Apr 2018; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03466411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466411.